Resonance Health Ltd · ASX:RHT
Resonance Health — H1 FY2026 Earnings Presentation
16 slides from Resonance Health's earnings presentation, Feb 27, 2026
Slide 1: Half Year Results FY26
Resonance Health Half Year Results FY26 Andrew Harrison, CEO Benjamin Carruthers, CFO 1 1
Slide 2: Highlights
Highlights ü 1H FY26 Revenue up 53% or $2.8M to $8.0M from 1H FY25 ü 1H FY26 Normalised EBITDA of $1.6M at 20% operating margin ü Profit after tax of $1.5 million (1H FY25: $1.0 million loss) ü Positive operating cashflow ü Major global pharma clinical trial execution progressing as planned ü Trials
Slide 3: Rapid scaling across 3 businesses
Significant revenue growth and diversification with rapid scaling across 3 businesses… FY23 FY26 Rapid scaling across 3 businesses Total Revenue $4.4M Full Year FY26 Guidance ü FY23–FY26 strong revenue growth (~45% CAGR) ü Profitable ~$2M EBITDA Total Revenue Guidance ~$17M ü Diversified revenue ü C
Slide 4: We continue to significantly expand our addressable global market
We continue to significantly expand our addressable global market… + CRO and Investigator site services ~$70b New Imaging Endpoints for + obesity and liver fibrosis Metabolic & Obesity VAT, SAT, MRE >$500m + liver fat market ~$300m + MRI Liver Iron 2023 Measurement market ~ $200M # Data compiled fro
Slide 5: More Customers
The strategy of getting a greater “share of wallet” expands on 3 vector's, more therapeutic areas, more services to each customer, and more customers through organic (SaMD) or acquisitive (buy expertise & footprint) growth. More sites – Geographic (Australia then overseas) More phases – Later stage
Slide 6: Growth strategy continues to bear early fruit
Growth strategy continues to bear early fruit… Therapeutic Services Area First Liver / Spleen Iron, then Site services - Australian global Haematology TrialsWest pharma First Liver / Spleen Iron, then central reading & US global pharma Haematology image storage Work Won Top 10 Indian global Metaboli
Slide 7: Strong Tailwinds
Strong Tailwinds Australian Clinical Trial Market Global Clinical Trial Market Key Drivers - Australia Key Drivers - Globally ü Approvals and regulatory system ü Increasing rapidity of technological breakthroughs ü Public private health system ü Shortening development timeframes ü Multi-cultural pop
Slide 8: While oncology dominates the global trial landscape, there is rapid growth in other therapeutic areas
While oncology dominates the global trial landscape, there is rapid growth in other therapeutic areas… # Data compiled from internal company market research 8
Slide 9: In the metabolic diseases space rapid growth is being driven by GLP-1-like drugs
In the metabolic diseases space rapid growth is being driven by GLP-1-like drugs # Data compiled from internal company market research 9
Slide 10: Resonance's deep expertise in liver and related metabolic / obesity areas
Resonance’s deep expertise in liver and related metabolic / obesity areas meets a significant opportunity… # Data compiled from internal company market research 10
Slide 11: Growth with financial discipline
Growth with financial discipline… Entrenched profitability ü Build revenue base ü Disciplined cost control ü Business transformation providing strong financial base with significant growth potential Generate strong FCF ü Operating cash flow positive ü Low sustaining capex ü Accretive expansion capex
Slide 12: 1HFY26 Profit & Loss
1HFY26 PROFIT & LOSS ü 53% revenue growth on pcp Profit & Loss Summary1 1HFY26 1HFY25 %Change Revenue $M 8.0 5.2 +53% ü 20% normalised EBITDA margin, significant operating leverage driving margin accretion in future Normalised EBITDA 1.6 (0.8) growth2 Normalised EBITDA Margin 20% -14% Statutory NPBT
Slide 13: 1HFY26 Balance Sheet
1HFY26 BALANCE SHEET Balance Sheet Summary1 $M 1HFY26 1HFY25 Assets Cash & Equivalents 2.7 3.0 Trade debtors and other receivables 3.5 3.5 Intangibles 9.4 9.5 ü Strong net cash position $2.7M PPE and other assets 2.3 1.9 ü $2.7M debt facility Liabilities Trade and other payables (1.6) (1.3) Borrowin
Slide 14: Business Outlook & Guidance
Business Outlook & Guidance Resonance enters 2H FY26 with: ü Continued delivery under global major pharmaceutical agreements ü Record SaMD forward orders and bid-tender pipeline ü Expanding and increasingly profitable TrialsWest operations ü Near-term milestones in fibrosis SaMD development and work
Slide 15: Disclaimer Forward Looking Statements
Disclaimer Forward Looking Statements This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause act
Slide 16: resonance-health-ltd/
Resonance i fh) esonance-health-Itd/